|
1
|
Bassig BA, Au WY, Mang O, Ngan R, Morton
LM, Ip DK, Hu W, Zheng T, Seow WJ, Xu J, et al: Subtype-specific
incidence rates of lymphoid malignancies in Hong Kong compared to
the United States, 2001–2010. Cancer Epidemiol. 42:15–23. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Uckun FM, Gaynon PS, Sensel MG, Nachman J,
Trigg ME, Steinherz PG, Hutchinson R, Bostrom BC, Sather HN and
Reaman GH: Clinical features and treatment outcome of childhood
T-lineage acute lymphoblastic leukemia according to the apparent
maturational stage of T-lineage leukemic blasts: A children's
cancer group study. J Clin Oncol. 15:2214–2221. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Aifantis I, Raetz E and Buonamici S:
Molecular pathogenesis of T-cell leukaemia and lymphoma. Nat Rev
Immunol. 8:380–390. 2008. View
Article : Google Scholar : PubMed/NCBI
|
|
4
|
Advani RH, Ansell SM, Lechowicz MJ, Beaven
AW, Loberiza F, Carson KR, Evens AM, Foss F, Horwitz S, Pro B, et
al: A phase II study of cyclophosphamide, etoposide, vincristine
and prednisone (CEOP) Alternating with Pralatrexate (P) as front
line therapy for patients with peripheral T-cell lymphoma (PTCL):
Final results from the T-cell consortium trial. Brit J Haematol.
172:535–544. 2016. View Article : Google Scholar
|
|
5
|
Kwong YL: T-cell Lymphoma forum. Exp Rev
Anticancer Ther. 10:493–498. 2010. View Article : Google Scholar
|
|
6
|
Pelengaris S, Khan M and Evan G: c-MYC:
More than just a matter of life and death. Nat Rev Cancer.
2:764–776. 2002. View
Article : Google Scholar : PubMed/NCBI
|
|
7
|
Malempati S, Tibbitts D, Cunningham M,
Akkari Y, Olson S, Fan G and Sears RC: Aberrant stabilization of
c-Myc protein in some lymphoblastic leukemias. Leukemia.
20:1572–1581. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Gregory MA, Qi Y and Hann SR:
Phosphorylation by glycogen synthase kinase-3 controls c-Myc
proteolysis and subnuclear localization. J Biol Chem.
278:51606–51612. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Pap M and Cooper GM: Role of glycogen
synthase kinase-3 in the phosphatidylinositol 3-kinase/Akt cell
survival pathway. J Biol Chem. 273:19929–19932. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Hetman M, Cavanaugh JE, Kimelman D and Xia
Z: Role of glycogen synthase kinase-3 beta in neuronal apoptosis
induced by trophic withdrawal. J Neurosci. 20:2567–2574. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Shankar SL, Krupski M, Parashar B, Okwuaka
C, O'Guin K, Mani S and Shafit-Zagardo B: UCN-01 alters
phosphorylation of Akt and GSK3beta and induces apoptosis in six
independent human neuroblastoma cell lines. J Neurochem.
90:702–711. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Querfeld C, Rizvi MA, Kuzel TM, Guitart J,
Rademaker A, Sabharwal SS, Krett NL and Rosen ST: The selective
protein kinase C beta inhibitor enzastaurin induces apoptosis in
cutaneous T-cell lymphoma cell lines through the AKT pathway. J
Invest Dermatol. 126:1641–1647. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Huang L, Wu SN and Xing D: High fluence
low-power laser irradiation induces apoptosis via inactivation of
Akt/GSK3β signaling pathway. J Cell Physiol. 226:588–601. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Cai Q, Deng H, Xie D, Lin TX and Lin TY:
Phosphorylated AKT protein is overexpressed in human peripheral
T-cell lymphomas and predicts decreased patient survival. Clin
Lymph Myeloma Leuk. 12:106–112. 2012. View Article : Google Scholar
|
|
15
|
Cicenas J: The potential role of Akt
phosphorylation in human cancers. Int J Biol Marker. 23:1–9. 2008.
View Article : Google Scholar
|
|
16
|
Wang QY, Wu S, Zhao X, Zhao C, Zhao H and
Huo L: Mechanisms of dihydroartemisinin and
dihydroartemisinin/holotransferrin cytotoxicity in T-cell lymphoma
cells. PLoS One. 10:e01373312015. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Zhang CZ, Zhang H, Yun J, Chen GG and Lai
PB: Dihydroartemisinin exhibits antitumor activity toward
hepatocellular carcinoma in vitro and in vivo. Biochem Pharmacol.
83:1278–1289. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Greenshields AL, Shepherd TG and Hoskin
DW: Contribution of reactive oxygen species to ovarian cancer cell
growth arrest and killing by the anti-malarial drug artesunate. Mol
Carcinogen. 56:75–93. 2017. View
Article : Google Scholar
|
|
19
|
Lu JJ, Meng LH, Shankavaram UT, Zhu CH,
Tong LJ, Chen G, Lin LP, Weinstein JN and Ding J:
Dihydroartemisinin accelerates c-MYC oncoprotein degradation and
induces apoptosis in c-MYC-overexpressing tumor cells. Biochem
Pharmacol. 80:22–30. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Liao K, Li J and Wang Z:
Dihydroartemisinin inhibits cell proliferation via
AKT/GSK3β/cyclinD1 pathway and induces apoptosis in A549 lung
cancer cells. Int J Clin Exp Pathol. 7:8684–8691. 2014.PubMed/NCBI
|
|
21
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta CT) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Mohamed AO, Hamid Abdel MM, Mohamed OS,
Elkando NS, Suliman A, Adam MA, Elnour FAA and Malik EM: Efficacies
of DHA-PPQ and AS/SP in patients with uncomplicated Plasmodium
falciparum malaria in an area of an unstable seasonal transmission
in Sudan. Malar J. 16:1632017. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Du W, Pang C, Xue Y, Zhang Q and Wei X:
Dihydroartemisinin inhibits the Raf/ERK/MEK and PI3K/AKT pathways
in glioma cells. Oncol Lett. 10:3266–3270. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Hou J, Wang D, Zhang R and Wang H:
Experimental therapy of hepatoma with artemisinin and its
derivatives: In vitro and in vivo activity, chemosensitization, and
mechanisms of action. Clin Cancer Res. 14:5519–5530. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Chen T, Li M, Zhang R and Wang H:
Dihydroartemisinin induces apoptosis and sensitizes human ovarian
cancer cells to carboplatin therapy. J Cell Mol Med. 13:1358–1370.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Heath-Engel HM, Chang NC and Shore GC: The
endoplasmic reticulum in apoptosis and autophagy: Role of the BCL-2
protein family. Oncogene. 27:6419–6433. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Fanidi A, Harrington EA and Evan GI:
Cooperative interaction between c-myc and bcl-2 proto-oncogenes.
Nature. 359:554–556. 1992. View
Article : Google Scholar : PubMed/NCBI
|
|
28
|
Yeh ES, Belka GK, Vernon AE, Chen CC, Jung
JJ and Chodosh LA: Hunk negatively regulates c-myc to promote
Akt-mediated cell survival and mammary tumorigenesis induced by
loss of Pten. Proc Natl Acad Sci USA. 110:6103–6108. 2013.
View Article : Google Scholar : PubMed/NCBI
|
